Short Interest in Heat Biologics Inc (HTBX) Rises By 14.5%

Heat Biologics Inc (NASDAQ:HTBX) saw a significant growth in short interest in March. As of March 31st, there was short interest totalling 2,869,626 shares, a growth of 14.5% from the March 15th total of 2,506,640 shares. Based on an average daily volume of 1,611,057 shares, the short-interest ratio is presently 1.8 days.

Shares of Heat Biologics (NASDAQ:HTBX) opened at 0.678 on Friday. The stock’s 50 day moving average price is $0.77 and its 200-day moving average price is $1.00. Heat Biologics has a 52-week low of $0.50 and a 52-week high of $3.35. The stock’s market cap is $22.73 million.

Heat Biologics (NASDAQ:HTBX) last posted its quarterly earnings data on Friday, March 31st. The biopharmaceutical company reported ($0.12) earnings per share for the quarter, missing the consensus estimate of ($0.07) by $0.05. The business had revenue of $0.12 million for the quarter, compared to analysts’ expectations of $0.13 million. On average, analysts predict that Heat Biologics will post ($0.63) earnings per share for the current fiscal year.

A number of large investors have recently bought and sold shares of the stock. Oxford Asset Management bought a new stake in Heat Biologics during the fourth quarter valued at $274,000. Sabby Management LLC bought a new stake in Heat Biologics during the first quarter valued at $2,176,000. KCG Holdings Inc. boosted its stake in Heat Biologics by 35.3% in the first quarter. KCG Holdings Inc. now owns 175,769 shares of the biopharmaceutical company’s stock valued at $156,000 after buying an additional 45,831 shares during the last quarter. Finally, Vanguard Group Inc. boosted its stake in Heat Biologics by 132.4% in the first quarter. Vanguard Group Inc. now owns 591,098 shares of the biopharmaceutical company’s stock valued at $526,000 after buying an additional 336,744 shares during the last quarter. Hedge funds and other institutional investors own 1.78% of the company’s stock.

A number of research analysts have commented on the company. Noble Financial restated a “buy” rating on shares of Heat Biologics in a research note on Sunday, May 14th. Zacks Investment Research lowered Heat Biologics from a “buy” rating to a “hold” rating in a research report on Friday, May 5th.

ILLEGAL ACTIVITY NOTICE: This report was published by Transcript Daily and is the property of of Transcript Daily. If you are accessing this report on another domain, it was stolen and republished in violation of U.S. & international trademark and copyright laws. The original version of this report can be read at https://transcriptdaily.com/2017/05/20/heat-biologics-inc-htbx-short-interest-up-14-5-in-march-updated-updated.html.

About Heat Biologics

Heat Biologics, Inc is a development-stage company focused on developing allogeneic, off-the-shelf cellular therapeutic vaccines to combat a range of cancers. The Company is an immuno-oncology company, which focuses on T cell-stimulating platform technologies, such as Immune Pan-Antigen Cytotoxic Therapy (ImPACT) and Combination Pan-Antigen Cytotoxic Therapy (ComPACT).

12 Month Chart for NASDAQ:HTBX

Receive News & Ratings for Heat Biologics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heat Biologics Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply